Eckert & Ziegler SE/€EUZ
1D1W1MYTD1Y5YMAX
Capital at risk
About Eckert & Ziegler SE
Eckert & Ziegler SE is a company operating in the pharmaceuticals industry, particularly specializing in the field of medical technology. It focuses on the development, production, and distribution of radioisotopes used for medical imaging, cancer treatment, and industrial applications. Some of its key products include low and high-energy sources used in brachytherapy and calibration sources for imaging devices. Founded in 1997, the company is headquartered in Berlin, Germany. Eckert & Ziegler SE leverages its technical expertise and regulatory experience to deliver specialized solutions, positioning itself as a critical provider in the healthcare and radiation therapy sectors.
- Ticker
- €EUZ
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 1,105
- Headquarters
- Berlin, Germany
- Website
- www.ezag.com
EUZ Metrics
BasicAdvanced
€773M
15.60
€0.79
1.47
€0.22
1.77%
Price and volume
Market cap
€773M
Beta
1.47
52-week high
€18.75
52-week low
€12.13
Average daily volume
114K
Dividend rate
€0.22
Financial strength
Current ratio
3.481
Quick ratio
2.649
Long term debt to equity
0.116
Total debt to equity
0.152
Dividend payout ratio (TTM)
27.68%
Interest coverage (TTM)
16.33%
Profitability
EBITDA (TTM)
88.662
Gross margin (TTM)
48.72%
Net profit margin (TTM)
15.92%
Operating margin (TTM)
24.07%
Effective tax rate (TTM)
31.34%
Revenue per employee (TTM)
€280,000
Management effectiveness
Return on assets (TTM)
10.30%
Return on equity (TTM)
20.14%
Valuation
Price to earnings (TTM)
15.601
Price to revenue (TTM)
2.483
Price to book
2.87
Price to tangible book (TTM)
3.48
Price to free cash flow (TTM)
32.716
Free cash flow yield (TTM)
3.06%
Free cash flow per share (TTM)
0.379
Dividend yield (TTM)
1.77%
Forward dividend yield
1.77%
Growth
Revenue change (TTM)
4.42%
Earnings per share change (TTM)
36.42%
3-year revenue growth (CAGR)
10.31%
10-year revenue growth (CAGR)
9.01%
3-year earnings per share growth (CAGR)
24.41%
10-year earnings per share growth (CAGR)
20.03%
3-year dividend per share growth (CAGR)
9.69%
10-year dividend per share growth (CAGR)
15.97%
Bulls say / Bears say
Medical segment adjusted EBIT rose 7% year-on-year to €24.9 million in H1 2026, driving a 31% segment margin and underscoring strong profitability in its core radiopharmaceutical business. (Reuters)
With €110.3 million in cash and securities against only €10.4 million in loan liabilities as of June 30, 2026, Eckert & Ziegler’s equity ratio strengthened to 57%, providing ample liquidity for strategic investments. (Reuters)
The June 2026 opening of the 9,500 sqm Jintan joint-venture facility with DC Pharma in China positions the company for local radioisotope production and taps into one of the fastest-growing nuclear medicine markets. (Reuters)
First-half 2026 net sales were essentially flat at €149.3 million versus €148.8 million a year earlier, highlighting a lack of top-line growth momentum. (Reuters)
The Isotope Products segment saw adjusted EBIT fall 24% to €9.4 million in H1 2026, with margins compressing to 13% due to an adverse product mix in industrial applications. (Reuters)
Eckert & Ziegler’s Americas revenue declined 5% to €64.9 million, with U.S. sales down 10% year-on-year amid timing differences in hot cell projects, underscoring volatility in its largest market. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2026.
Upcoming events
No upcoming events
Funds containing EUZ
AllEURUSDGBP
Fund name | Fund size | €EUZ weighting |
|---|---|---|
iShares TecDAX€EXS2 | €645M | 0.41% |
iShares Healthcare Innovation$HEAL | $1.4B | 0.07% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.07% |
iShares Healthcare Innovation£DRDR | £1B | 0.07% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.